Hemokinin 1 (human) (trifluoroacetate salt)
(Synonyms: HK-1, TGKASQFFGLM-NH2, Thr-Gly-Lys-Ala-Ser-Gln-Phe-Phe-Gly-Leu-Met-NH2) 目录号 : GC49882A peptide agonist of NK1 receptors
Sample solution is provided at 25 µL, 10mM.
Hemokinin 1 is a tachykinin peptide neurokinin-1 (NK1) receptor agonist.1,2,3,4,5 It induces migration of A375 and B16/F10 melanoma cells when used at a concentration of 1 µM, an effect that can be reversed by the NK1 receptor antagonist L-732,138 .1 Hemokinin 1 (0.001-0.1 µM) promotes the proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs).2 It induces the production of prostaglandin E2 in human colon mucosal and muscle explants.3 Intracerebroventricular administration of hemokinin 1 increases the latency to withdrawal in the tail-flick test in mice in a dose-dependent manner.4 It decreases mean arterial pressure (MAP) and heart rate in anesthetized rats when administered at doses ranging from 1 to 30 nmol/kg.5
1.Zhang, Y., Li, X., Li, J., et al.Human hemokinin-1 promotes migration of melanoma cells and increases MMP-2 and MT1-MMP expression by activating tumor cell NK1 receptorsPeptides838-15(2016) 2.Song, H., Yin, W., Zeng, Q., et al.Hemokinins modulate endothelium function and promote angiogenesis through neurokinin-1 receptorInt. J. Biochem. Cell Biol.44(9)1410-1421(2012) 3.Dai, L., Perera, D.S., King, D.W., et al.Hemokinin-1 stimulates prostaglandin E2 production in human colon through activation of cyclooxygenase-2 and inhibition of 15-hydroxyprostaglandin dehydrogenaseJ. Pharmacol. Exp. Ther.340(1)27-36(2012) 4.Fu, C.Y., Zhao, Y.L., Dong, L., et al.In vivo characterization of the effects of human hemokinin-1 and human hemokinin-1(4-11), mammalian tachykinin peptides, on the modulation of pain in miceBrain Behav. Immun.22(6)850-860(2008) 5.Kong, Z.-Q., Fu, C.-Y., Chen, Q., et al.Cardiovascular responses to intravenous administration of human hemokinin-1 and its truncated form hemokinin-1(4-11) in anesthetized ratsEur. J. Pharmacol.590(1-3)310-316(2008)
Cas No. | SDF | Download SDF | |
别名 | HK-1, TGKASQFFGLM-NH2, Thr-Gly-Lys-Ala-Ser-Gln-Phe-Phe-Gly-Leu-Met-NH2 | ||
Canonical SMILES | CSCC[C@@H](C(N)=O)NC([C@H](CC(C)C)NC(CNC([C@H](CC1=CC=CC=C1)NC([C@@H](NC([C@H](CCC(N)=O)NC([C@H](CO)NC([C@H](C)NC([C@H](CCCCN)NC(CNC([C@@H](N)[C@H](O)C)=O)=O)=O)=O)=O)=O)CC2=CC=CC=C2)=O)=O)=O)=O.OC(C(F)(F)F)=O | ||
分子式 | C54H84N14O14S • XCF3COOH | 分子量 | 1185.4 |
溶解度 | Water: soluble | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.8436 mL | 4.218 mL | 8.436 mL |
5 mM | 0.1687 mL | 0.8436 mL | 1.6872 mL |
10 mM | 0.0844 mL | 0.4218 mL | 0.8436 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet